Immutep Limited

16/12/2025

Immutep Limited today reports strong operational progress in the global TACTI-004 Phase III trial evaluating efti in combination with MSD’s anti-PD-1 therapy, KEYTRUDA®, and chemotherapy as first-line therapy for advanced/metastatic non-small cell lung cancer.

Updates include:
- The TACTI-004 trial has enrolled 289 patients globally, representing over 38% of targeted enrolment
- Global progress continues, with more than 120 activated clinical sites and 27 countries having received full regulatory approvals, including the United States

Read the full announcement here: https://bit.ly/44r6rTV

12/12/2025

Great to be mentioned in The Australian today off the back of announcing our collaboration with Dr. Reddy's on Monday.

Scott Power, Senior Research Analyst at Morgans said: "That was a pretty big deal that Immutep announced with Dr.Reddy's and is providing them with important funding from an upfront payment and depending on clinical success there will be more milestone payments come through."

"The deal has put Immutep in a solid position and the share price has responded positively."

Thanks to Nadine McGrath & Scott Power for the mention.

Full article here:

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 27 years, gives his take on the ASX healthcare sector for the week and his ‘Powerplay’ stock pick.

08/12/2025

Immutep Limited is pleased to announce a new strategic collaboration and exclusive licensing agreement with Dr. Reddy's Laboratories Ltd. for the development and commercialisation of efti in all countries outside North America, Europe, Japan, and Greater China.

Marc Voigt, CEO of Immutep said: “The license agreement with Dr. Reddy’s is a major commercial milestone for Immutep and further validates the significant potential of efti, our first-in-class cancer immunotherapy.”

“Dr. Reddy’s is a global pharmaceutical company with proven capabilities in the markets they have licensed for efti. This makes them an ideal partner for us to maximise the commercial benefits from efti outside of North America, Europe, Japan and China. Having recently launched Zytorvi® (toripalimab) as the first and only immunotherapy for nasopharyngeal cancer in Australia, Dr. Reddy’s has a strong track record of bringing cancer therapies to patients.”

“In addition to the upfront payment, we stand to earn substantive future milestone and royalty payments. Importantly, we preserve full commercial rights in the world’s largest pharmaceutical markets so we are very well-positioned for future value creation while also maintaining full control of efti’s manufacturing globally, including to Dr. Reddy’s.”

Full announcement here: https://bit.ly/3KNPQmu

13/11/2025

Immutep has announced positive data from the EFTISARC-NEO Phase II trial evaluating efti in combination with radiotherapy and pembrolizumab for resectable soft tissue sarcoma (STS).

The novel combination achieved a significant 51.5% median tumour hyalinization/fibrosis across multiple STS subtypes, including rare and aggressive tumours with poor prognosis.

The promising results warrant further investigation of this novel combination in registrational settings.

Click here to see the ASX: https://bit.ly/4p5Pkid

10/11/2025

Immutep Limited is pleased to share that the EFTISARC-NEO clinical trial evaluating neoadjuvant efti in soft tissue sarcomas has been awarded second place in the distinguished Golden Scalpel Award competition.

This competition recognises the most innovative solutions in Polish medicine and is presented by independent experts to initiatives that set new standards in advancing healthcare.

This year, EFTISARC-NEO was the only oncology project to receive this accolade, underscoring its leadership and breakthrough potential in cancer treatment.

To learn more visit: https://bit.ly/43W9jaZ

Immutep extends its gratitude to the patients and dedicated team at MSCNRIO whose efforts made this achievement possible.

Nasze badanie w zasadzie zmienia myślenie o mięsakach. To absolutnie nowy kierunek w terapii, który realnie poprawia rokowanie pacjentów – mówi dr n. med. Paulina Jagodzińska-Mucha z Zespołu Narodowego Instytutu Onkologii, który zajął drugie miejsce w konkursie Złoty Skalpel 2025.

20/10/2025

Immutep Limited is pleased to share positive clinical data presented at the Congress 2025

Key highlights:
- EFTISARC-NEO Phase II: Met primary endpoint, with the novel combination including efti achieving 51.5% tumour hyalinization/fibrosis in soft tissue sarcoma (p < 0.001). https://bit.ly/3IVVQsF

- INSIGHT-003 trial: Generated strong response rates across all PD-L1 expression levels 1L NSCLC, including 61.7% in low & no PD-L1 (TPS

12/10/2025

Immutep Limited is pleased to complete another productive meeting with the FDA regarding the eftilagimod alfa (efti) program. We welcome the positive feedback and the agreement on efti's optimal biological dose is another important building block for future potential BLA filings.

Announcement here: http://bit.ly/4ogdyWA

09/10/2025

Immutep Limited announces update for pivotal TACTI-004 Phase III in 1L NSCLC.

Immutep has now enrolled & randomised over 170 patients, an important milestone as this is above the # required to conduct the futility analysis, which remains on track for Q1 2026.

Additionally, the # of activated clinical sites continues to expand at a strong pace, now exceeding 100 across 24 countries.

Read more here: http://bit.ly/42wziFq

22/09/2025

We’re pleased to share that George Washington University Cancer Center, will launch an investigator-initiated Phase II trial evaluating neoadjuvant efti as monotherapy and in combination with chemotherapy prior to surgery in HR+/HER2-neg breast cancer patients. The trial is led by Dr. Pavani Chalasani, MD, MPH, Division Director of Hematology and Medical Oncology and aims to assess pathological complete response (pCR) following neoadjuvant efti and chemotherapy treatment.

Read more here http://bit.ly/3W6wBqd

16/09/2025

Immutep Limited CEO Marc Voigt recently joined ShareCafe’s Lauren Hays to share an updated company presentation and discuss Immutep's latest developments.

Marc spoke about:
- Progress of the pivotal TACTI-004 Phase 3 trial in first-line non-small cell lung cancer, run in collaboration with Merck/MSD
- The company’s broader oncology and autoimmune pipeline, including the IMP761 program
- Key milestones and catalysts to watch for the remainder of 2025 and beyond

Watch the full discussion here: http://bit.ly/4673Wrb

Immutep (ASX:IMM, NASDAQ:IMMP) is developing late-stage immunotherapies for cancer and autoimmune disease centred on the LAG-3 protein. Marc Voigt, CEO, says the company is leveraging its diversified pipeline of five programs, including lead candidate eftilagimod alpha (efti) in oncology and IMP761....

08/09/2025

Immutep Limited CEO Marc Voigt will be joining the ShareCafe- Sip and Learn webinar this Thursday, 11 September at 12:30pm AEST.

Marc will deliver a company presentation and take part in the Q&A session.

Use this link to register if you'd like to join in!

This free webinar gives viewers the opportunity to hear from and engage with a range of ASX-listed micro/small cap company's. Company presentations will come from: - Etherstack (ASX:ESK) - Olympio Metals (ASX:OLY) - Rural Funds Group (ASX:RFF) - Immutep (ASX:IMM) Time: 12:30 PM AEST Day: Thursday, 1...

08/09/2025

Immutep Limited is pleased to announce an abstract for the EFTISARC-NEO Phase II investigator-initiated trial has been accepted for oral presentation at the Connective Tissue Oncology Society (CTOS) 2025 Annual Meeting taking place 12-15 November 2025, in Boca Raton, Florida.

For more details see https://lnkd.in/gZVbAdTw